Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519447 | 0.87 | KMO (0.63) | KMORXRARXRBBCL2ACMSD | |
| Benzoic Acid SCHEMBL29163749 | 0.87 | EPHX2 (0.57) | KMOLMNAGAAEPHX2NR1H4 | |
| SCHEMBL29577419 | 0.87 | KMO (0.87) | KMOLMNAGAARXRARXRB | |
| SCHEMBL14683877 | 0.87 | KMO (0.87) | KMOLMNAGAARXRARXRB | |
| SCHEMBL1855849 | 0.86 | KMO (0.67) | KMOLMNAGAAEPHX2NR1H4 | |
| SCHEMBL3220396 | 0.85 | KMO (0.91) | KMOLMNAGAARXRARXRB | |
| SCHEMBL437537 | 0.84 | KMO (0.91) | KMOLMNAGAARXRARXRB | |
| SCHEMBL8581943 | 0.84 | KMO (0.51) | KMOEPHX2NR1H4BCL2FOLH1 | |
| Hydrochloric Acid SCHEMBL1853944 | 0.84 | KMO (0.65) | KMOLMNAGAAEPHX2NR1H4 | |
| SCHEMBL10243325 | 0.84 | BCL2 (0.71) | KMOLMNAGAAEPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007519744-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | claimed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | claimed |
| US-9556103-B2 | Biphenyl esters, their production and their use in the manufacture of plasticizers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150361027-A1 | Biphenyl Esters, Their Production and Their Use in the Manufacture of Plasticizers | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-12-17 | — | — | US | disclosed |
| WO-2015191281-A1 | BIPHENYL ESTERS, THEIR PRODUCTION AND THEIR USE IN THE MANUFACTURE OF PLASTICIZERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-5700938-A | Intermediates for imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5618969-A | Intermediates for imidazopyridines | EISAI CO., LTD. (JP) | 1997-04-08 | — | — | US | disclosed |
| US-5608068-A | Process for the preparation of imidazopyridine derivatives and intermediates | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| US-5587504-A | Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5583229-A | Process for the preparation of imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5559236-A | Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5557002-A | Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists | EISAI CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5554757-A | Process for the preparation of imidazopyridine derivatives, and intermediates therefore | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0627433-A1 | PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE | Eisai Co., Ltd. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361027-A1 | Biphenyl Esters, Their Production and Their Use in the Manufacture of Plasticizers | CYP19A1, CYP1B1, CYP1A1 | KMO 2075/4885LMNA 3165/4885GAA 3082/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | KMO 190/4885LMNA 3198/4885GAA 2559/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | KMO 1212/4885LMNA 1400/4885GAA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.